Boundless Bio Inc

Audentes Therapeutics doing business as Astellas Gene Therapies, Inc. is a biotechnology company that serves as the Gene Therapy Center of Excellence. The company is divided into three divisions that specialize in gene therapy research, including technical operations, medical and development, and future commercialization of gene therapy programs. Audentes Therapeutics was acquired by Astellas Pharma on January 15, 2020.

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company was founded by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt, and Jonathan E. Lim on April 10, 2018 and is headquartered in San Diego, CA.

Company elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial Third ecDTx program advancing, with plans for development candidate nomination by mid-2025 Operating runway extended into 2027, through anticipated clinical readout for BBI-355 and key development milestones for third ecDTx program Klaus Wagner, M.D., Ph.D., Chief Medical Officer, and Neil Abdollahian, Chief Business Officer, stepping down; James L.

Boundless Bio Announces Pipeline and Leadership Updates

Boundless Bio, Inc. (BOLD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Boundless Bio, Inc. (BOLD) Loses -19.52% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in Piper Sandler's 36th Annual Healthcare Conference.

Boundless Bio to Participate in the Piper Sandler Healthcare Conference

Enrollment progressing in BBI-355 POTENTIATE and BBI-825 STARMAP clinical trials, with initial proof-of-concept data expected in the second half of 2025

Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in the 2024 Guggenheim Global Healthcare Conference.

Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference

SAN DIEGO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, and Jami Rubin, Chief Financial Officer, will participate in the 2024 Cantor Global Healthcare Conference.

Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference

Boundless Bio, Inc. (BOLD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -31.59% in 4 Weeks, Here's Why You Should You Buy the Dip in Boundless Bio, Inc. (BOLD)

BBI-355 POTENTIATE clinical trial ongoing with initiatives implemented to expedite enrollment in combination cohorts; initial proof-of-concept data now expected in the second half of 2025

Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, and Jami Rubin, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. The fireside chat session is schedul.

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results for the first quarter of 2024 and highlighted recent progress. “It has been an exciting quarter at Boundless Bio. The Phase 1/2 POTENTIATE trial of BBI-355, our potentially best-in-class, oral, selective CHK1 inhibitor.

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Boundless Bio Chief Financial Officer, Jami Rubin, will present at the Citizens JMP Life Sciences Conference 2024. The podium presentation is scheduled for Monday, May 13, in New York, NY, at 1:00 p.m. ET. A live and archived webca.

Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that the first patient has been dosed with BBI-825 in a first-in-human, Phase 1/2 clinical trial for patients with locally advanced or metastatic cancer with resistance gene amplifications (NCT06299761). ecDNA are a key driver of high c.

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, presents preclinical and clinical pharmacodynamic data on its lead ecDNA-directed therapy (ecDTx), BBI-355, and research on ecDNA-mediated acquired resistance to chemotherapy at the American Association for Cancer Research (AACR) Annual Meeting 2024. B.

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Aldeyra Therapeutics

Clearway Energy

Five Star Bancorp

GAMCO Natural Resources. Gold & Income Trust

Although the number and size of insider purchases have been somewhat lower as the second quarter begins, the following beneficial owners and other insiders were still showing their love for these five stocks.

Insiders Scoop Up Shares of These 5 Stocks for the Second Quarter

IB Acquisition Corp

Alta Global Group Ltd

Mobile-Health Network Solutions

Netclass Technology Inc

U-BX Technology Ltd

Waystar Holding Corp

ZEEKR Intelligent Technology Holding Ltd

Three IPOs and one SPAC debuted this past week, while three IPOs submitted initial filings - Boundless Bio, U-BX Technology, Alta Global, and IB Acquisition, respectively. Three IPOs submitted initial filings this week - Marex Group, Reitar Logtech and NetClass.

U.S. IPO Weekly Recap: Biotech Leads Short 3 IPO Week

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio, Inc. (Nasdaq: BOLD), a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at an initial public offering price of $16.00 per share. All of the shares are being offered by Boundless Bio. The gross proceeds from the offering.

Boundless Bio Announces Pricing of Initial Public Offering

Astera Labs Inc

Auna SA

Black Hawk Acquisition Corp

Intelligent Group Ltd

Reddit Inc

Four IPOs (Astera Labs, Reddit, Auna & Intelligent Group) priced this past week, joined by one SPAC (Black Hawk Acquisition). Two sizable issuers submitted initial filings - Centuri Holdings and Ibotta.

U.S. IPO Weekly Recap: Tech IPOs Pop As End Of March Approaches

Boundless Bio, Inc. has filed for a $100 million IPO to develop DNA treatments for various cancers. The firm's lead candidate, BBI-355, is in Phase 1 trials for the treatment of oncogene amplified cancers. The global market for solid tumor cancer treatments is forecasted to reach $532 billion by 2032, providing a large addressable market for Boundless Bio's technologies.

Boundless Bio Starts $100 Million U.S. IPO Plan

News for Boundless Bio Inc Stock (BOLD)